Filana Therapeutics (FLNA) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on detecting and treating central nervous system disorders, including TSC-related epilepsy.

• Utilizes a proprietary scientific and clinical platform to develop first-in-class therapies, with simufilam as the lead product candidate.

• Incorporated in Delaware in 1998 and headquartered in Austin, Texas.

Financial performance and metrics

• As of September 30, 2025, had 48,307,896 shares of common stock outstanding and a historical net tangible book value of $81.4 million ($1.69 per share).

• After the offering, as adjusted net tangible book value would be $129.9 million ($2.02 per share), resulting in immediate dilution of $1.09 per share to new investors at an assumed offering price of $3.11.

Use of proceeds and capital allocation

• Net proceeds from the offering will be used for general corporate purposes and working capital, including development of simufilam for TSC-related epilepsy.

• Management retains broad discretion over allocation; potential uses include capital expenditures, licensing, acquisitions, and investments.

• Pending use, proceeds may be invested in commercial paper, government/non-government debt, or money market funds.